Expanding Digital Foundations for a Growing Cell & Gene Therapy Innovator

A leading cell and gene therapy innovator is scaling its operations and needed to extend its digital backbone to meet the demands of GMP operations. As part of this growth, the organization expanded its utilization of the Oracle ERP system. The Wave 3 rollout was designed to unify Finance, Procurement, Supply Chain, Clinical Supply, QC, and QA functions on a single integrated platform.

Challenge:

Prior to Wave 3, many of the organization’s core business processes were siloed, requiring manual work and limiting cross-functional collaboration. The company needed an end-to-end system that could deliver:

• Real-time and accurate data
• Advanced reporting and dashboards
• Enhanced controls and traceability
• Seamless collaboration across departments
• Reduced manual processes

Ensuring adoption across diverse business areas while maintaining regulatory rigor was a critical requirement.

Solution:

Osprey Life Sciences partnered with the client to provide program management expertise, coordinating across IT, business stakeholders, and vendor teams. The Osprey expert worked closely with solution architects and product owners to ensure the phased rollout met both operational and compliance needs.

Key components of the solution included:

• Managing cross-departmental alignment across IT, Finance, Procurement, Supply Chain, Clinical Supply, QC, and QA.
• Overseeing vendor coordination to deliver technical enhancements.
• Driving testing readiness, including extensive User Acceptance Testing (UAT) to validate system performance.
• Implementing enhanced Oracle ERP capabilities to automate workflows, strengthen controls, and improve collaboration.

Results:

The Oracle Wave 3A rollout successfully launched in August 2025, delivering:

• Integrated operations across Finance, Procurement, Supply Chain, and Quality functions.
• Real-time access to accurate data with improved reporting and dashboards.
• Increased efficiency through reduced manual work and automated processes.
• Enhanced traceability and compliance controls, critical for GMP operations.
• Stronger cross-functional collaboration, enabling teams to work seamlessly across shared systems.

While testing and UAT required significantly more effort than initially anticipated, the partnership between Osprey, the architect, and other parties, ensured readiness by delivering hundreds of hours of UAT support and expanded bug fixes during hypercare, mitigating risks and ensuring stability post-launch.

Client Feedback:

“Thank you so much for your great leadership and program management for this mission-critical Digital Enhancement Oracle release.”